Abstract: Various embodiments of an tracheal tube having a sensor coupled to a selectively permeable membrane are provided. In some embodiments, the membrane may be permeable to one or more blood gases and/or blood analytes. Certain embodiments of the endotracheal tube may be capable of deploying the sensor during intubation to sense one or more indicators of blood flow characteristics, such as a level of blood gases and/or blood analytes, in the respiratory tract. Embodiments of the present invention may include positioning of the sensor in a variety of suitable positions with respect to the permeable membrane, such as mounting the sensor to the underside of an inflatable permeable membrane.

Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository-comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided.

Abstract: A luminescent solar concentrator apparatus includes an optically transparent substrate and a photovoltaic material layer at least partially embedded within an optically transparent encapsulant material layer that contacts the optically transparent substrate. A luminescent material layer also contacts the optically transparent encapsulant material layer. Generally, the luminescent solar concentrator apparatus provides that the luminescent material layer is not located within an incoming optical pathway through at least the optically transparent substrate to the photovoltaic material layer.

Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided.

Abstract: A rail fence retractor allowing removal of a fence rail engaged with a fence post comprising a blade having a first and second end. The first end of the blade is configured for insertion into a fence post slot having a rail inserted therein. The rail has self-locking tabs which must be depressed for removal of the rail from the fence post slot. The fence rail retractor also has a handle which is attached to the second end of the blade. The handle allows the application of force against handle to fix the position of the handle against the fence post during removal of the rail from the fence post slot. The handle is also useful in carrying the rail fence retractor when not in use. The handles may be also be configured to allow a pair of rail fence retractors to fit or snap together when not in use.

Abstract: A system for launching an unmanned aerial vehicle (UAV) payload includes a launch tube, liquid rocket, and launch control assembly. The rocket is positioned in the launch tube and contains the UAV payload. A booster assembly may include a canister partially filled with liquid. A gas cylinder is filled with compressed gas. The liquid is pre-pressurized by the gas or mixed with the gas right before launch such that, upon launch, liquid and gaseous thrust stages launch the rocket to a threshold altitude. The UAV payload deploys after reaching the threshold altitude. Optional stability tubes may be connected to the launch tube, which may be buoyant for water-based operations. An optional tether may be connected to the liquid rocket for arresting its flight prior to reaching apogee. The UAV payload is not launched directly by the gas/liquid mix. A method of launching the UAV payload is also disclosed.

Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg.

Abstract: A propulsion device for a marine vessel, the propulsion device comprising an electrical machine with integral magnetic gearing, which comprises three members, namely a first or inner rotor comprising a first plurality of permanent magnets, a second rotor in the form of a plurality of ferromagnetic pole pieces, and a stator which is associated with a plurality of 3-phase windings and to the periphery of which a plurality of second permanent magnets are fixed. The magnetic pole piece rotor is connected to a drive shaft provided with a propulsion means for providing propulsion to the marine vessel. The first or inner rotor is free to rotate about the drive shaft. The pole pieces of the second rotor are arranged to magnetically couple the permanent magnets of the first or inner rotor to the second permanent magnets on the stator.

Abstract: The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.

Abstract: Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.

Abstract: Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C?CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

Abstract: The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.

Abstract: A fire detection system for monitoring a volume containing fluid, typically air, for the presence of smoke particles is disclosed. A conduit for receiving the fluid, and any smoke particles therein, and directing the fluid to a smoke detector has a plurality of inlets formed therein. A respective temperature sensor is associated with each of the inlets which generate a signal indicative of a change in temperature in the region of the inlet. In the embodiments, the temperature sensor comprises one or more fiber Bragg gratings. The fiber Bragg gratings preferably have different grating periods. The reflected light from each fiber Bragg grating is returned back down the fiber optic cable and redirected via a 2×1 coupler to a wavelength detection system and a personal computer.

Abstract: Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

Abstract: Various embodiments of an tracheal tube having a sensor coupled to a selectively permeable membrane are provided. In some embodiments, the membrane may be permeable to one or more blood gases and/or blood analytes. Certain embodiments of the endotracheal tube may be capable of deploying the sensor during intubation to sense one or more indicators of blood flow characteristics, such as a level of blood gases and/or blood analytes, in the respiratory tract. Embodiments of the present invention may include positioning of the sensor in a variety of suitable positions with respect to the permeable membrane, such as mounting the sensor to the underside of an inflatable permeable membrane.

Abstract: Various embodiments of a tracheal tube having a sensor disposed on a non-sealing portion of a cuff are provided. Certain embodiments of the tracheal tube may be capable of deploying the sensor during intubation to sense one or more indicators of blood flow characteristics, such as a level of blood gases and/or blood analytes, in the respiratory tract. The sensor on the cuff may be configured to deploy upon inflation of the cuff and to return to its predeployment position upon deflation of the cuff. The sensor may be further adapted to abut the tracheal mucosa of a patient or not contact the tracheal wall at all during deployment.

Abstract: Various embodiments of a tracheal tube having a mechanically deployable sensor are provided. Certain embodiments of the tracheal tube may be capable of mechanically deploying the sensor during intubation to sense one or more indicators of blood flow characteristics, such as a level of blood gases and/or blood analytes, in the respiratory tract. The mechanically deployable sensor may be configured to abut the tracheal mucosa of a patient or not contact the tracheal wall at all during deployment. The sensor may be further adapted to remain in a recess disposed in the tracheal tube prior to deployment and exit the recess when acquiring measurements.

Abstract: Azetidine derivatives of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer; liver steatosis; and non-alcoholic steatohepatitis.

Abstract: The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

Abstract: A polymer-dispersed liquid crystal based display is embedded inside a lightguide illuminator sheet which provides illumination of the display without the need for a backlight or frontlight. Light from one or more light sources is coupled into the lightguide sheet and is guided within a range of high angles of incidence within the sheet by total internal reflection. The guided light illuminating portions of the display which are in diffusing state is scattered such that some of the light is allowed to escape total internal reflection, providing visibility of the display. Guided light illuminating portions of the display which are in non-diffusing state remains guided within the lightguide illuminator sheet. Combining multiple lightguide embedded displays can be used to provide a three-dimensional display.